Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children.

Sahakyan, Gayane; Grigoryan, Svetlana; Wasley, Annemarie; Mosina, Liudmila; Sargsyan, Shushan; Asoyan, Ara; Gevorgyan, Zaruhi; Kocharyan, Karine; Avagyan, Tigran; Lopman, Benjamin; Vanyan, Artavazd; Khactatryan, Sergey; Parashar, Umesh D; Cortese, Margaret M.
Clin Infect Dis; 62 Suppl 2: S147-54, 2016 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-27059349


The Republic of Armenia was 1 of the 2 earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program to reduce the burden of rotavirus disease (documented to cause 38% of acute gastroenteritis hospitalizations [AGE] among children aged <5 years). In November 2012, RV1 (Rotarix) was introduced for Armenian infants at ages 6 and 12 weeks.


The established active surveillance system at 2 hospitals in the capital, Yerevan, whereby children aged <5 years hospitalized for AGE have stool sample tested for rotavirus antigen, was used to assess trends in rotavirus hospitalizations. Immunization records on children enrolled after vaccine introduction were obtained from clinics, and vaccine effectiveness (VE) was estimated using children with AGE who test negative for rotavirus as controls for the rotavirus-positive cases.


Among infants, rotavirus hospitalizations were reduced by 48% within the first year after introduction, and by ≥75% in years 2 and 3 following introduction. Reductions of ≥30% in other young children too old to have been vaccinated suggest additional benefit through indirect protection; overall in year 3, rotavirus hospitalizations were reduced by 69% among children aged <5 years. The overall VE of 2 RV1 doses in protecting against rotavirus hospitalization (any severity) was 62% (95% confidence interval [CI], 36%-77%) among children aged 6-23 months; 68% (95% CI, 24%-86%) among those aged 6-11 months, and 60% (95% CI, 20%-80%) in children aged 12-23 months. Against more severe rotavirus disease, VE was 79% (95% CI, 55%-90%) and similarly high in both age groups.


RV1 is effective in young Armenian children and substantially reduced rotavirus hospitalizations shortly after introduction.
Selo DaSilva